Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Trial Profile

A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Preeclampsia; Radiation injuries
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors A1M Pharma AB
  • Most Recent Events

    • 09 Apr 2019 According to an A1M Pharma AB media release, the first subject has been dosed in this trial. The results of the first phases are expected to be available in about six months.
    • 21 Mar 2019 According to an A1M Pharma AB media release, the study will begin with screening of healthy subjects for 1-2 weeks, followed by dosing in the first dose group. The results of the first phases anticipated approximately six months after dosing the first participant.
    • 21 Mar 2019 Status changed from planning to recruiting, as reported in an A1M Pharma AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top